our u.s. compounding , inc. , subsidiary , or usc , which we acquired in april 2016 and which is registered as a drug compounding outsourcing facility under section 503b of the u.s. food , drug & cosmetic act , as amended , or fdca , and the u.s. drug quality and security act , or dqsa , provides prescription compounded medications , including compounded sterile preparations and nonsterile compounds , to patients , physician clinics , hospitals , surgery centers and other clients throughout most of the united states . usc 's product offerings broadly include , among others , corticosteroids , hormone replacement therapies , hospital outsourcing products , injectables , urological preparations , ophthalmic preparations , topical compounds for pain and men 's and women 's health products . usc 's compounded formulations in many circumstances are offered as alternatives to drugs approved by the fda . usc also provides certain veterinary pharmaceutical products for animals . to achieve our goals and support our overall strategy , we will need to raise a substantial amount of funding and make significant investments in , among other things , new product development and working capital . symjepi ( epinephrine ) injection 0.3mg product on june 15 , 2017 , fda approved the company 's symjepi ( epinephrine ) injection 0.3mg product for the emergency treatment of allergic reactions ( type i ) including anaphylaxis . symjepi ( epinephrine ) injection 0.3mg is intended to deliver a dose of epinephrine , which is used for emergency , immediate administration in acute anaphylactic reactions to insect stings or bites , allergic reaction to certain foods , drugs and other allergens , as well as idiopathic or exercise-induced anaphylaxis . on november 27 , 2017 , we submitted an snda to the fda for a lower dose version ( 0.15mg ) . symjepi ( epinephrine ) injection 0.3mg is designed for patients weighing 66 pounds or greater . the lower dose symjepi ( epinephrine ) injection 0.15mg product candidate is intended for patients weighing 33 to 66 pounds . on february 9 , 2018 , we received correspondence from the fda indicating that the agency had determined that the snda was sufficiently complete to permit a substantive review . the agency indicated that no potential review issues were identified as of the date of the correspondence and that if no major deficiencies were identified in the agency 's continued review , the agency was targeting september 3 , 2018 , to communicate proposed labeling and , if necessary , any post-marketing requirement or commitment requests . there can be no assurances regarding the timing of outcome of the fda 's review of our snda . in connection with our process of exploring commercialization options for symjepi ( epinephrine ) injection 0.3mg in the u.s. market after the fda approval , we retained an investment bank to assist us . we determined to engage in a process with the goal of maximizing the value of the asset . the process has been ongoing and as of the date of this report , we are in discussions with potential partners regarding commercialization of the product . however , the timing of a commercial launch will depend on a number of factors , including without limitation whether we enter into an agreement with a commercialization partner and , if we enter into such an agreement , the terms of any such agreement and the plans of the commercialization partner . as a result , there are no assurances regarding whether we will enter into an agreement with a commercialization partner , when we may enter into any such agreement , or the date of a commercial launch of symjepi ( epinephrine ) injection 0.3mg . if we do not enter into an agreement with a commercialization partner , then we anticipate that we would seek to commercialize the product ourselves , which would require additional expenditures . 44 going concern and management plan our independent registered public accounting firm has included a “ going concern ” explanatory paragraph in its report on our financial statements for the years ended december 31 , 2017 and 2016 indicating that we have incurred recurring losses from operations and are dependent on additional financing to fund operations , and that these conditions raise substantial doubt about our ability to continue as a going concern . as of december 31 , 2017 , we had cash and cash equivalents of approximately $ 18.3 million , including approximately $ 1.0 million in restricted cash , an accumulated deficit of approximately $ 114.0 million , and liabilities of approximately $ 11.9 million . we anticipate that we will need significant funding during 2018 to continue operations , satisfy our obligations , fund the future expenditures that we believe will be required to support commercialization of our products and conduct the clinical and regulatory work to develop our product candidates . such additional funding may not be available , may not be available on reasonable terms , and could result in significant additional dilution to our stockholders . if we do not obtain required additional equity or debt funding , our cash resources will be depleted and we could be required to materially reduce or suspend operations , which would likely have a material adverse effect on our business , stock price and our relationships with third parties with whom we have business relationships , at least until additional funding is obtained . the above conditions raise substantial doubt about our ability to continue as a going concern . story_separator_special_tag sales discounts and rebates are sometimes offered to customers if specified criteria are met . additionally , sales are generally made with a limited right of return under certain conditions . revenues are recorded net of provisions for sales discounts and returns , which are established at the time of sale . cost of sales . our cost of sales includes direct and indirect costs to manufacture formulations and sell products , including active pharmaceutical ingredients , personnel costs , packaging , storage , royalties , shipping and handling costs , the write-off of obsolete inventory and other related expenses . accounts receivable . accounts receivable are reported at the amount management expects to collect on outstanding balances . management provides for probable uncollectible amounts through a charge to earnings and credit to allowance for doubtful accounts . uncollectible amounts are based on usc 's history of past write-offs and collections and current credit conditions . inventories . inventories are valued at the lower of cost or net realizable value . the cost of inventories is determined using the first-in , first-out ( “ fifo ” ) method . inventories consist of compounding formulation raw materials , work-in-process , currently marketed products , and device supplies . monthly , the company reviews the expiration dates of the raw materials , work-in-process and finished goods inventory , and a reserve for obsolescence is recorded based on the expiration dates . acquisitions and intangibles . the company has engaged in business combination activity . the accounting for business combinations requires management to make judgments and estimates of the fair value of assets acquired , including the identification and valuation of intangible assets , as well as liabilities assumed . such judgments and estimates directly impact the amount of goodwill recognized in connection with each acquisition , as goodwill represents the excess of the purchase price of an acquired business over the fair value of its net tangible and identifiable intangible assets . 49 go odwill and other long-lived assets . goodwill , which has an indefinite useful life , represents the excess of purchase consideration over fair value of net assets acquired . goodwill is reviewed for impairment at least annually as of december 31 each year , or more frequently if events occur indicating the potential for impairment . during its goodwill impairment review , the company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount , including goodwill . the qualitative factors include , but are not limited to , macroeconomic conditions , industry and market considerations , and the overall financial performance and outlook of the company . if , after assessing the totality of these qualitative factors , the company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount , then no additional assessment is deemed necessary . otherwise , the company proceeds to perform the two-step test for goodwill impairment . the first step involves comparing the estimated fair value of the reporting unit with its carrying value , including goodwill . if the carrying amount of the reporting unit exceeds its fair value , the company performs the second step of the goodwill impairment test to determine the amount of loss , which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill . the company evaluates its long-lived assets with definite lives , such as property and equipment , acquired technology , customer relationships , patent and license rights , for impairment by considering competition by products prescribed for the same indication , the likelihood and estimated future entry of non-generic and generic competition with the same or similar indication and other related factors . the factors that drive the estimate of the life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review . recoverability is measured by comparison of the assets ' book value to future net undiscounted cash flows that the assets are expected to generate . we performed an impairment analysis as of december 31 , 2017 and 2016 , and no impairment of goodwill or acquired intangibles was identified . claims liabilities . our usc subsidiary was self-insured up to certain limits for health insurance through february 28 , 2017. beginning march 1 , 2017 , usc elected to participate in a fully insured health insurance plan . the claims payable related to the self-insured plan at december 31 , 2017 and 2016 was $ 0 and approximately $ 126,000 , respectively . deferred income taxes . deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the tax basis of such assets and liabilities . the company maintains a valuation allowance against its deferred tax assets due to the uncertainty regarding the future realization of such assets , which is based on historical taxable income , projected future taxable income and the expected timing of the reversals of existing temporary differences . until such time as the company can demonstrate that it will no longer incur losses , or if the company is unable to generate sufficient future taxable income , it could be required to maintain the valuation allowance against its deferred tax assets . the tax cuts and jobs act was enacted on december 22 , 2017. the tax cuts and jobs act includes a number of changes to existing u.s. tax laws , most notably the reduction of the u.s. corporate income tax rate from 35 % to 21 % , beginning in 2018. at december 31 , 2017 , the company had not completed its accounting assessment for the tax effects of the enactment of the act ; however , the company believes that it has

liquidity and capital resources we have incurred net losses of approximately $ 25.5 million and $ 19.4 million for years ended december 31 , 2017 and 2016 , respectively . since our inception , june 6 , 2006 , and through december 31 , 2017 , we have an accumulated deficit of approximately $ 114.0 million . since inception and through december 31 , 2017 , we have financed our operations principally through debt financing and through public and private issuances of common stock and preferred stock . since inception , we have raised a total of approximately $ 135 million in debt and equity financing transactions , consisting of approximately $ 23.5 million in debt financing and approximately $ 111.4 million in equity financing transactions . we anticipate that we will need significant additional funding during 2018 to satisfy our obligations and fund the future expenditures that we believe will be required to support commercialization of our products and conduct the clinical and regulatory work to develop our product candidates . we expect to finance future cash needs primarily through proceeds from equity or debt financings , loans , sales of assets , out-licensing transactions , and or collaborative agreements with corporate partners , and from revenues from our sale of compounded pharmacy formulations . we have used the net proceeds from debt and equity financings for general corporate purposes , which have included funding for research and development , selling , general and administrative expenses , working capital , reducing indebtedness , pursuing and completing acquisitions or investments in other businesses , products or technologies , and for capital expenditures . assuming adequate funding , we anticipate that we may make capital expenditures during 2018 of at least approximately $ 5 million to $ 6 million including , without limitation , expenditures relating to a new usc facility and the construction of manufacturing assembly lines for our symjepi ( epinephrine ) injection 0.3mg product and naloxone ( apc-6000 ) product candidate .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources we have incurred net losses of approximately $ 25.5 million and $ 19.4 million for years ended december 31 , 2017 and 2016 , respectively . since our inception , june 6 , 2006 , and through december 31 , 2017 , we have an accumulated deficit of approximately $ 114.0 million . since inception and through december 31 , 2017 , we have financed our operations principally through debt financing and through public and private issuances of common stock and preferred stock . since inception , we have raised a total of approximately $ 135 million in debt and equity financing transactions , consisting of approximately $ 23.5 million in debt financing and approximately $ 111.4 million in equity financing transactions . we anticipate that we will need significant additional funding during 2018 to satisfy our obligations and fund the future expenditures that we believe will be required to support commercialization of our products and conduct the clinical and regulatory work to develop our product candidates . we expect to finance future cash needs primarily through proceeds from equity or debt financings , loans , sales of assets , out-licensing transactions , and or collaborative agreements with corporate partners , and from revenues from our sale of compounded pharmacy formulations . we have used the net proceeds from debt and equity financings for general corporate purposes , which have included funding for research and development , selling , general and administrative expenses , working capital , reducing indebtedness , pursuing and completing acquisitions or investments in other businesses , products or technologies , and for capital expenditures . assuming adequate funding , we anticipate that we may make capital expenditures during 2018 of at least approximately $ 5 million to $ 6 million including , without limitation , expenditures relating to a new usc facility and the construction of manufacturing assembly lines for our symjepi ( epinephrine ) injection 0.3mg product and naloxone ( apc-6000 ) product candidate .
```    
 Suspicious Activity Report : our u.s. compounding , inc. , subsidiary , or usc , which we acquired in april 2016 and which is registered as a drug compounding outsourcing facility under section 503b of the u.s. food , drug & cosmetic act , as amended , or fdca , and the u.s. drug quality and security act , or dqsa , provides prescription compounded medications , including compounded sterile preparations and nonsterile compounds , to patients , physician clinics , hospitals , surgery centers and other clients throughout most of the united states . usc 's product offerings broadly include , among others , corticosteroids , hormone replacement therapies , hospital outsourcing products , injectables , urological preparations , ophthalmic preparations , topical compounds for pain and men 's and women 's health products . usc 's compounded formulations in many circumstances are offered as alternatives to drugs approved by the fda . usc also provides certain veterinary pharmaceutical products for animals . to achieve our goals and support our overall strategy , we will need to raise a substantial amount of funding and make significant investments in , among other things , new product development and working capital . symjepi ( epinephrine ) injection 0.3mg product on june 15 , 2017 , fda approved the company 's symjepi ( epinephrine ) injection 0.3mg product for the emergency treatment of allergic reactions ( type i ) including anaphylaxis . symjepi ( epinephrine ) injection 0.3mg is intended to deliver a dose of epinephrine , which is used for emergency , immediate administration in acute anaphylactic reactions to insect stings or bites , allergic reaction to certain foods , drugs and other allergens , as well as idiopathic or exercise-induced anaphylaxis . on november 27 , 2017 , we submitted an snda to the fda for a lower dose version ( 0.15mg ) . symjepi ( epinephrine ) injection 0.3mg is designed for patients weighing 66 pounds or greater . the lower dose symjepi ( epinephrine ) injection 0.15mg product candidate is intended for patients weighing 33 to 66 pounds . on february 9 , 2018 , we received correspondence from the fda indicating that the agency had determined that the snda was sufficiently complete to permit a substantive review . the agency indicated that no potential review issues were identified as of the date of the correspondence and that if no major deficiencies were identified in the agency 's continued review , the agency was targeting september 3 , 2018 , to communicate proposed labeling and , if necessary , any post-marketing requirement or commitment requests . there can be no assurances regarding the timing of outcome of the fda 's review of our snda . in connection with our process of exploring commercialization options for symjepi ( epinephrine ) injection 0.3mg in the u.s. market after the fda approval , we retained an investment bank to assist us . we determined to engage in a process with the goal of maximizing the value of the asset . the process has been ongoing and as of the date of this report , we are in discussions with potential partners regarding commercialization of the product . however , the timing of a commercial launch will depend on a number of factors , including without limitation whether we enter into an agreement with a commercialization partner and , if we enter into such an agreement , the terms of any such agreement and the plans of the commercialization partner . as a result , there are no assurances regarding whether we will enter into an agreement with a commercialization partner , when we may enter into any such agreement , or the date of a commercial launch of symjepi ( epinephrine ) injection 0.3mg . if we do not enter into an agreement with a commercialization partner , then we anticipate that we would seek to commercialize the product ourselves , which would require additional expenditures . 44 going concern and management plan our independent registered public accounting firm has included a “ going concern ” explanatory paragraph in its report on our financial statements for the years ended december 31 , 2017 and 2016 indicating that we have incurred recurring losses from operations and are dependent on additional financing to fund operations , and that these conditions raise substantial doubt about our ability to continue as a going concern . as of december 31 , 2017 , we had cash and cash equivalents of approximately $ 18.3 million , including approximately $ 1.0 million in restricted cash , an accumulated deficit of approximately $ 114.0 million , and liabilities of approximately $ 11.9 million . we anticipate that we will need significant funding during 2018 to continue operations , satisfy our obligations , fund the future expenditures that we believe will be required to support commercialization of our products and conduct the clinical and regulatory work to develop our product candidates . such additional funding may not be available , may not be available on reasonable terms , and could result in significant additional dilution to our stockholders . if we do not obtain required additional equity or debt funding , our cash resources will be depleted and we could be required to materially reduce or suspend operations , which would likely have a material adverse effect on our business , stock price and our relationships with third parties with whom we have business relationships , at least until additional funding is obtained . the above conditions raise substantial doubt about our ability to continue as a going concern . story_separator_special_tag sales discounts and rebates are sometimes offered to customers if specified criteria are met . additionally , sales are generally made with a limited right of return under certain conditions . revenues are recorded net of provisions for sales discounts and returns , which are established at the time of sale . cost of sales . our cost of sales includes direct and indirect costs to manufacture formulations and sell products , including active pharmaceutical ingredients , personnel costs , packaging , storage , royalties , shipping and handling costs , the write-off of obsolete inventory and other related expenses . accounts receivable . accounts receivable are reported at the amount management expects to collect on outstanding balances . management provides for probable uncollectible amounts through a charge to earnings and credit to allowance for doubtful accounts . uncollectible amounts are based on usc 's history of past write-offs and collections and current credit conditions . inventories . inventories are valued at the lower of cost or net realizable value . the cost of inventories is determined using the first-in , first-out ( “ fifo ” ) method . inventories consist of compounding formulation raw materials , work-in-process , currently marketed products , and device supplies . monthly , the company reviews the expiration dates of the raw materials , work-in-process and finished goods inventory , and a reserve for obsolescence is recorded based on the expiration dates . acquisitions and intangibles . the company has engaged in business combination activity . the accounting for business combinations requires management to make judgments and estimates of the fair value of assets acquired , including the identification and valuation of intangible assets , as well as liabilities assumed . such judgments and estimates directly impact the amount of goodwill recognized in connection with each acquisition , as goodwill represents the excess of the purchase price of an acquired business over the fair value of its net tangible and identifiable intangible assets . 49 go odwill and other long-lived assets . goodwill , which has an indefinite useful life , represents the excess of purchase consideration over fair value of net assets acquired . goodwill is reviewed for impairment at least annually as of december 31 each year , or more frequently if events occur indicating the potential for impairment . during its goodwill impairment review , the company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount , including goodwill . the qualitative factors include , but are not limited to , macroeconomic conditions , industry and market considerations , and the overall financial performance and outlook of the company . if , after assessing the totality of these qualitative factors , the company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount , then no additional assessment is deemed necessary . otherwise , the company proceeds to perform the two-step test for goodwill impairment . the first step involves comparing the estimated fair value of the reporting unit with its carrying value , including goodwill . if the carrying amount of the reporting unit exceeds its fair value , the company performs the second step of the goodwill impairment test to determine the amount of loss , which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill . the company evaluates its long-lived assets with definite lives , such as property and equipment , acquired technology , customer relationships , patent and license rights , for impairment by considering competition by products prescribed for the same indication , the likelihood and estimated future entry of non-generic and generic competition with the same or similar indication and other related factors . the factors that drive the estimate of the life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review . recoverability is measured by comparison of the assets ' book value to future net undiscounted cash flows that the assets are expected to generate . we performed an impairment analysis as of december 31 , 2017 and 2016 , and no impairment of goodwill or acquired intangibles was identified . claims liabilities . our usc subsidiary was self-insured up to certain limits for health insurance through february 28 , 2017. beginning march 1 , 2017 , usc elected to participate in a fully insured health insurance plan . the claims payable related to the self-insured plan at december 31 , 2017 and 2016 was $ 0 and approximately $ 126,000 , respectively . deferred income taxes . deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the tax basis of such assets and liabilities . the company maintains a valuation allowance against its deferred tax assets due to the uncertainty regarding the future realization of such assets , which is based on historical taxable income , projected future taxable income and the expected timing of the reversals of existing temporary differences . until such time as the company can demonstrate that it will no longer incur losses , or if the company is unable to generate sufficient future taxable income , it could be required to maintain the valuation allowance against its deferred tax assets . the tax cuts and jobs act was enacted on december 22 , 2017. the tax cuts and jobs act includes a number of changes to existing u.s. tax laws , most notably the reduction of the u.s. corporate income tax rate from 35 % to 21 % , beginning in 2018. at december 31 , 2017 , the company had not completed its accounting assessment for the tax effects of the enactment of the act ; however , the company believes that it has

